Regentis Biomaterials logo

Regentis Biomaterials(NYSEMKT) RGNT

Market Cap$11.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-78%
5 YearN/A
1 YearN/A
1 Month-14%
$1.62
-0.31%
-0.01Today
After hours$1.47-$0.16 (-9.57%)
Regentis Biomaterials last closing stock price
MetricPriceDate
Last closeUSD 1.632026-10-13
Regentis Biomaterials stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.52%USD 1.652026-10-06
1 month-14.02%USD 1.892026-09-11
3 month-33.13%USD 2.432026-07-15
Year to date-75.89%USD 6.742025-12-31
Since inception-78.33%USD 7.502025-12-04

Regentis Biomaterials Financials at a Glance

Market Cap

$11.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

-$2.45

P/E Ratio

-0.66

Dividend

$0.00

Beta (Volatility)

3.43 (High)

Price

$1.62

Volume

132,641

Open

$1.65

Previous Close

$1.51

Daily Range

$1.45 - $1.65

52-Week Range

$1.23 - $15.50

Estimated Earnings Date

Jun 30, 2026

RGNT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine firm focused on innovative solutions for tissue repair. The company aims to enhance patients' health and quality of life through its advanced medical technologies.

Products and Services
  • GelrinC: A cell-free hydrogel for knee injury treatment
  • Proprietary Gelrin platform for biodegradable hydrogel implants
  • Orthopedic therapies for tissue regeneration
Growth Outlook
  • Established in 2004, Regentis has a strong foundation in regenerative medicine
  • Focus on orthopedic therapies aligns with increasing global demand for innovative treatments
  • Potential for market expansion as GelrinC progresses through development stages
Financial Highlights
  • Market capitalization of approximately $12.29 million
  • Stock price range between $1.23 and $15.50 over the past year
  • Beta of -0.69 indicates lower volatility compared to the overall market
Regentis Biomaterials Ltd. operates in the Medical - Instruments & Supplies industry, with a commitment to developing groundbreaking therapies. The flagship product, GelrinC, is designed to address knee injuries and articular cartilage damage, showcasing the company's dedication to improving patient outcomes. With a market capitalization of around $12.29 million, Regentis is positioned for potential growth as it navigates the complexities of the healthcare sector. The stock has experienced a significant price range over the past year, reflecting both the challenges and opportunities within the market. The company's negative beta suggests a lower risk profile compared to broader market fluctuations, making it an intriguing option for investors interested in the regenerative medicine space.
AI Generated • Sep 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

10

CEO

Eli Hazum, PhD, EMBA

Website

www.regentis.co.il

Headquarters

Herzliya, TA 4676652, IL

RGNT Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-1.52%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$11.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.02M

Volume

132.64K

Avg. Volume

74.93K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Regentis Biomaterials Performance Analysis

Regentis Biomaterials annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Regentis Biomaterials annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -3.81N/A
20232023-12-31USD -0.85-77.7%
20242024-12-31USD 0.96N/A
20252025-12-31USD -2.64N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$11.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MAHNMid-Atlantic Home Health Network, Inc.
$0.07+0.00%
IGNEIgene Biotechnology, Inc.
$0.00+0.00%
ACRACRES Commercial Realty Corp.
$9.99-1.38%
ALFCenturion Acquisition Corp.
$10.83-0.82%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$51.39-4.76%
NVDANvidia
$221.30-3.16%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About RGNT

What is the current price of Regentis Biomaterials?

Regentis Biomaterials is trading at $1.51 per share.

What is the 52-week range for Regentis Biomaterials?

Over the past 52 weeks, Regentis Biomaterials has traded between $1.23 and $15.50.

How much debt does Regentis Biomaterials have?

As of the most recent reporting period, Regentis Biomaterials reported total debt of $1.20M.

How much cash does Regentis Biomaterials have on hand?

Regentis Biomaterials reported $7.38M in cash and cash equivalents in its most recent financial results.

What is Regentis Biomaterials’s dividend yield?

Regentis Biomaterials does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services